Toric IOLs reduce astigmatism more than PCRIs

Article

Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a recently published study.

Both toric IOLs and peripheral corneal relaxing incisions (PCRIs) reduce astigmatism, but toric IOLs do so to a greater extent as well as being more predictable, according to results of a study recently published in the Journal of Cataract & Refractive Surgery.

For this prospective masked bilateral randomized study, researchers from Moorfields Eye Hospital NHS Foundation Trust, London, enrolled 30 patients (60 eyes) with a preoperative corneal astigmatism of 1.0 to 2.5 D. All patients received a toric IOL in one eye and nontoric IOL plus PCRI in the other eye. Postoperative follow-up was done at 1 hour, 1 month and 6 months to measure uncorrected distance visual acuity, corrected distance visual acuity, autorefraction and subjective refraction. The IOL axis was assessed with retroillumination photos.

Researchers found a statistically significant difference in the mean astigmatism vector reduction in the toric IOL group compared with the PCRI group (1.74 D vs 1.27 D, respectively; P = 0.042). Mean absolute rotation of the toric IOL was 2.5 degrees (maximum 6.3 degrees) in the first 6 months postoperatively. Astigmatism increased in the PCRI group between the 1-month and the 6-month follow-up (mean: 0.38 D; maximum: 1.00 D; P

To view the abstract of this study, click here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.